XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Total Lisata Therapeutics, Inc. Stockholders' Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Common stock, beginning balance (in shares) at Dec. 31, 2022     7,867,000          
Beginning balance at Dec. 31, 2022 $ 66,324 $ 66,578 $ 8 $ 574,548 $ (29) $ (507,241) $ (708) $ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (15,475) (15,475)       (15,475)    
Share-based compensation (in shares)     114,000          
Share-based compensation 1,474 1,474   1,474        
Net proceeds from issuances of common stock (in shares)     76,000          
Net proceeds from issuances of common stock 297 297   297        
Proceeds from option exercises (in shares)     83,000          
Proceeds from option exercises 155 155   155        
Unrealized gain on marketable securities 1 1     1      
Foreign currency translation adjustment (72) (72)     (72)      
Common stock, ending balance (in shares) at Sep. 30, 2023     8,140,000          
Ending balance at Sep. 30, 2023 52,704 52,958 $ 8 576,474 (100) (522,716) (708) (254)
Common stock, beginning balance (in shares) at Jun. 30, 2023     8,133,000          
Beginning balance at Jun. 30, 2023 57,714 57,968 $ 8 576,173 (50) (517,455) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (5,261) (5,261)       (5,261)    
Share-based compensation (in shares)     7,000          
Share-based compensation 301 301   301        
Foreign currency translation adjustment (50) (50)     (50)      
Common stock, ending balance (in shares) at Sep. 30, 2023     8,140,000          
Ending balance at Sep. 30, 2023 $ 52,704 52,958 $ 8 576,474 (100) (522,716) (708) (254)
Common stock, beginning balance (in shares) at Dec. 31, 2023 8,149,897   8,151,000          
Beginning balance at Dec. 31, 2023 $ 47,894 48,148 $ 8 576,971 (42) (528,081) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (15,375) (15,375)       (15,375)    
Share-based compensation (in shares)     155,000          
Share-based compensation 875 875   875        
Net proceeds from issuances of common stock (in shares)     14,000          
Net proceeds from issuances of common stock $ 32 32   32        
Proceeds from option exercises (in shares) 0              
Unrealized gain on marketable securities $ 3 3     3      
Foreign currency translation adjustment $ 7 7     7      
Common stock, ending balance (in shares) at Sep. 30, 2024 8,319,600   8,320,000          
Ending balance at Sep. 30, 2024 $ 33,436 33,690 $ 8 577,878 (32) (543,456) (708) (254)
Common stock, beginning balance (in shares) at Jun. 30, 2024     8,322,000          
Beginning balance at Jun. 30, 2024 37,995 38,249 $ 8 577,552 (77) (538,526) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (4,930) (4,930)       (4,930)    
Share-based compensation (in shares)     (2,000)          
Share-based compensation 326 326   326        
Unrealized gain on marketable securities 12 12     12      
Foreign currency translation adjustment $ 33 33     33      
Common stock, ending balance (in shares) at Sep. 30, 2024 8,319,600   8,320,000          
Ending balance at Sep. 30, 2024 $ 33,436 $ 33,690 $ 8 $ 577,878 $ (32) $ (543,456) $ (708) $ (254)